Achievers Strengthens Customer Leadership with Sixteen Total Accolades in G2's Spring 2025 Reports
TORONTO--(BUSINESS WIRE)-- Achievers, the world's most utilized recognition and reward software, announced today it has earned 16 badges across multiple categories in G2's Spring 2025 Grid® Reports. These accolades reinforce Achievers' unmatched ability to boost employee engagement and retention, fuel culture and business transformation through behavior change, and deliver measurable business results.
Known and trusted for its enterprise-grade recognition platform anchored in workforce science, Achievers empowers over 4 million users across nearly 190 countries. One of Achievers' standout differentiators is its unmatched adoption and usage – employees using Achievers receive 13 recognitions annually on average, twice the rate of other recognition platforms. The level of user engagement was solidified by G2: Achievers earned a coveted Leader spot in G2's Spring 2025 Enterprise Grid® for Employee Recognition Software report, fueled by exceptional user feedback and market momentum. With over 1,600 five-star reviews, users consistently highlight Achievers' ability to recognize both everyday efforts and major milestones, integrate seamlessly into daily workflows, and provide robust reporting and insights. Customers also benefit from exceptional support and innovative, consistent recognition and reward experiences.
'At Achievers, our customers aren't just recognizing more, they're recognizing moments that matter seamlessly with science-backed strategies,' said David Bator, Managing Director, Achievers Workforce Institute. 'The impact is clear: they're doubling productivity and engagement rates, shaping resilient cultures, delivering better service, and witnessing stronger ROI. With 16 G2 badges and over 1,600 five-star reviews, our customers aren't just seeing results, they're helping 90 million G2 users understand what makes our approach to recognition so unique and effective. We're incredibly grateful for our passionate, vocal, and loyal user community.'
In addition to earning a spot as a Leader on the Enterprise Grid® for Employee Recognition, Achievers ranked as a Leader on G2's Spring 2025 Enterprise Grid® for Employee Experience and a Leader on the Mid-Market Grid® Report for Employee Engagement. Achievers was also named on the Enterprise Canada Regional Grid® Reports for Employee Recognition, Employee Engagement, and Employee Experience. Additional G2 accolades Achievers received this spring include badges for Momentum Leader for Employee Engagement and Employee Recognition, High Performer in Canada for both Employee Engagement and Employee Experience, as well as High Performer Enterprise for Employee Recognition. Achievers also earned the title of Regional Leader in Canada, Asia Pacific, and Europe for the same areas – bringing the total to 16 G2 badges earned in Spring 2025.
Achievers' exceptional rankings in G2's Spring 2025 Grid Reports build on a milestone year for the recognition category leader.
Achievers recently unveiled an AI assistant, a recognition toolkit, and new reward features, equipping customers with sophisticated tools to address the $438 billion management disengagement crisis. Its unwavering commitment to innovation and global excellence continues to earn industry acclaim.
In April 2025, Achievers announced that it ranked as a Leader in Everest Group's Rewards and Recognition (R&R) Solutions PEAK Matrix® Assessment for the third consecutive time, also securing the #1 spot for vision and capability.
Earlier in the year, Achievers and its customer Seattle Children's Hospital were honored in the Brandon Hall Group Excellence Awards for their work empowering patients and families to recognize their healthcare providers, an initiative that set a new standard for employee appreciation in the healthcare industry.
G2 is the world's largest and most trusted online software marketplace. Every year, over 90 million people, including those working at major companies, use G2 to help them choose the best software based on real feedback from other users. G2 scores products and vendors based on reviews gathered from its user community and aggregated data from online sources and social networks. The G2 Star Rating is calculated by aggregating reviewers' answers to its 'Likely to Recommend' question (1–10 scale) and dividing the average in half. Its software scoring system leverages two proprietary scoring components, Satisfaction and Market Performance to determine overall G2 score and Grid placement.
For more information about G2's methodology, visit https://research.g2.com/methodology.
To demo the Achievers recognition and rewards platform, visit our website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
38 minutes ago
- Business Wire
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd ('Avistone'), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the clinical data for Vebreltinib plus Andamertinib (PLB1004), its innovative combination of potent mesenchymal-epithelial transition factor (MET) inhibitor and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. The details of the poster presentation are provided below: Poster title: Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression after failure on EGFR-TKIs treatment: phase Ib/II KYLIN-1 study Abstract Number For Publication: 8632 Session: Poster Session-Lung Cancer- Non-Small Cell Metastatic Location: Poster Board, 112 Session Date/Time: 5/31/2025 1:30pm-4:30pm CDT MET amplification or overexpression is the most common 'off-target' mechanism that drives resistance to EGFR-TKIs in NSCLC patients. The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed that Vebreltinib plus Andamertinib demonstrated notable efficacy and manageable safety in EGFR-mutated NSCLC patients with MET amplification or overexpression after EGFR-TKIs failure. Among the 56 patients enrolled at a dose of Vebreltinib 150mg BID plus Andamertinib 80mg QD (RP2D), the confirmed overall response rate (ORR) was 50.0%, and the median progression-free survival (mPFS) was 9.9 months. In 19 patients with brain metastases, ORR was 42.1% and mPFS was 9.5 months. Grade 3 or higher treatment related adverse events (TRAEs) occurred in 19.6% of the patients. None discontinued treatment or died due to TRAEs. No new safety signal was observed. A multicenter Phase III study, KYLIN-3 study (NCT06970782), is currently ongoing to further evaluate Vebreltinib plus Andamertinib versus platinum-based doublet chemotherapy in patients with EGFR mutations, MET amplification and/or overexpression, locally advanced or metastatic NSCLC following EGFR-TKI failure. To obtain a copy of the poster, please email Avistone. About Vebreltinib Vebreltinib is an orally, potent and selective c-Met inhibitor. Chinese National Medical Products Administration (NMPA) has formally approved the use of Vebreltinib in locally advanced or metastatic NSCLC patients with MET exon 14 skipping mutations, as well as adult patients with isocitrate dehydrogenase mutant astrocytoma with the PTPRZ1-MET fusion gene or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion gene and have failed previous treatments. Currently, Chinese Center for Drug Evaluation (CDE) has formally accepted its New Drug Application (NDA) and granted it priority review, intended for patients with locally advanced or metastatic NSCLC with MET amplification. About Andamertinib (PLB1004) Andamertinib (PLB1004) is an oral, potent, irreversible, and selective EGFR-TKI with potent blood-brain barrier penetration and broad tyrosine kinase activity. Preclinical studies have shown that it can effectively and irreversibly target exon 20 insertion. Additionally, it can also potently target classical EGFR mutations, such as Del19, L858R and T790M with a high degree of selectivity. About Avistone Biotechnology Beijing Avistone Biotechnology Co., Ltd. ('Avistone') is an innovative biotechnology company dedicated to precision therapies with significant unmet medical needs for patients worldwide. Avistone maintains an extensive pipeline of targeted therapies in Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.
Yahoo
2 hours ago
- Yahoo
AG1 Expands Into Retail With Costco Wholesale (NasdaqGS:COST) Nationwide Partnership
Costco Wholesale recently announced a noteworthy retail partnership with AG1, marking a significant channel expansion into brick-and-mortar stores. This development, alongside the company's strong financial performance, aligns with the broader 1.7% market rise over the past month. Despite a market climbing 11% over the year, Costco's 4.59% increase is likely bolstered by its revenue growth and innovative product launches, such as the DripDrop® Hydration variety pack. These factors collectively contribute positively to the company's momentum and complement the general upward market trend, illustrating a robust overall positioning. Every company has risks, and we've spotted 1 weakness for Costco Wholesale you should know about. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. The recent retail partnership between Costco and AG1 represents a meaningful channel expansion, potentially enhancing revenue and earnings forecasts. This move into brick-and-mortar stores could elevate sales volumes and support e-commerce initiatives, while further boosting Costco's diversification efforts across its international markets. Over the past five years, Costco's total shareholder return of 262.00% underscores its consistent performance and growth strategies, contrasting the more modest 4.59% increase over the last year compared to a rising market. This longer-term return showcases an impressive trajectory, highlighting Costco's ability to generate significant returns to investors. With the price target set at US$1052.04, slightly above the current share price of US$1010.50, analysts view Costco as being relatively fairly priced, aligning closely with projected earnings growth and market expectations. The slight discount to the price target suggests the potential for alignment between corporate growth initiatives and market sentiment. Relative to the consumer retailing industry, Costco's 1-year return of 4.59% reflects a performance under the market's 11.5% gain; however, its 5-year performance highlights a formidable ability to achieve sustained growth. This context helps investors consider both short-term dynamics and longer-term growth opportunities. Gain insights into Costco Wholesale's past trends and performance with our report on the company's historical track record. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:COST. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
BIOSIG TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of BioSig Technologies, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed merger of BioSig Technologies, Inc. (NasdaqCM: BSGM) and Streamex Exchange Corporation. Upon closing of the proposed transaction, current BioSig shareholders and holders of common stock equivalents will hold 25% of the fully diluted BioSig common stock outstanding. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to BioSig shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
